Hedge Fund - Sarissa Capital Management

Alex Denner Bio, Returns, AUM, Net Worth

Sarissa Capital Management, founded by Dr. Alexander John Denner in 2012, is headquartered in Greenwich, Connecticut. This hedge fund focuses primarily on stocks of companies within the healthcare industry.

Dr. Denner gained valuable experience as a portfolio manager during his tenure at Andreas Halvorsen’s Viking Global, which ended in 2006. Following this, he served as Senior Managing Director at Carl Icahn’s Icahn Capital LP for six years. At Icahn Capital, Denner developed an activist strategy in healthcare, contributing to some of the firm’s most successful investments, including positions in Genzyme, Biogen Inc (NASDAQ:BIIB), and ImClone. Additionally, he has served on the boards of several healthcare companies, including ARIAD Pharmaceuticals Inc and Enzon Pharmaceuticals, and currently holds leadership roles at Biogen and The Medicines Company (NASDAQ:MDCO). Dr. Denner holds an S.B. degree from the Massachusetts Institute of Technology and M.S., M.Phil., and PhD degrees from Yale University.

Sarissa Capital Management manages discretionary assets totaling $926,987,169 across 10 clients, according to their Form ADV filed on March 29, 2024. Their latest 13F filing for Q1 2024 reported $571,629,246 in managed 13F securities, with their top 10 holdings accounting for 100% of this amount. The firm's largest holding is Ironwood Pharmaceuticals Inc., with 16,390,000 shares.

Alex Denner
Fund Profile
Filing Period:
Fund Name: Sarissa Capital Management
Manager Alex Denner
Portfolio Value $592,420,772
Change This QTR +1.04%
Filing Period:
Last update:
No. Security Ticker Shares Value Activity % Port History
1. BIIB 643,000 $149,060,260 25.16%
2. INVA 7,277,000 $119,342,800 20.14%
3. IRWD 16,390,000 $106,862,800 18.03%
4. GILD 1,103,282 $75,696,178 12.77%
5. CYTK 1,110,000 $60,139,800 +270% 10.15%
News, Interviews and Investor Letters